EMA conditionally approves Pfizer's Paxlovid for high-risk adults
The European Medicines Agency grants conditional approval for Paxlovid, an oral antiviral, to treat high-risk adults with COVID-19. The decision follows positive trial data and supports home-based treatment options.
Herald Premium Archive
This report is for subscribers
Sign in or choose a plan for full access to every Belfast Herald story and the complete archive.
HealthEMA conditionally approves Pfizer's Paxlovid for high-risk adults
Sign in or subscribeBrowse free archive reportsThe European Medicines Agency grants conditional approval for Paxlovid, an oral antiviral, to treat high-risk adults with COVID-19. The decision follows positive trial data and supports home-based treatment options.